Protocol Ledger

NCT05349721 · Phase II · TERMINATED

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

Interventional Phase II clinical trial protocol NCT05349721 sponsored by PTC Therapeutics in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-05-15 Enrollment: 336 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05349721
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)336 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05349721
Protocol FieldVerified Registry Value
NCT IdentifierNCT05349721
Consolidated Lead SponsorPTC Therapeutics
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase II
Overall Recruitment StatusTERMINATED
Registered Enrollment336 participants (ACTUAL)
Registered Start Date2022-05-15
WhyStopped ClassificationStrategic / Business / Sponsor Decision

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05349721
Hospital Research SiteLocationSite Profile
UCI Health and Chao Family Comprehensive Cancer CenterOrange, CAOpen Hospital Dossier ->
Augusta UniversityAugusta, GAOpen Hospital Dossier ->
University of Nebraska Medical CenterOmaha, NEOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI